REGiMMUNE Ltd (瑞格國際生技) yesterday inked an agreement with CTBC Securities Co (中國信託證券) as part of its plans for an initial public offering (IPO) by 2021.
The Tokyo-based Japanese biopharmaceutical company, which focuses on immunotherapies for rare diseases, cancer and debilitating disorders, was founded in 2006.
It has decided to restructure itself and move its headquarters to Taiwan, as there is more young talent here, chief executive officer Kenzo Kosuda told a news conference in Taipei.
Photo: Huang Pao-hui, Taipei times
The company recruited five employees after establishing a research center in Nangang Biotech Incubation Center (南港生技育成中心), and is looking to hire more for the development of its new antibody drugs RGI-AB01 and RGI-AB02, Kosuda said.
“In Japan, young graduates tend to look for lifetime employment at big companies, and seldom show interest in small ones like us, but Taiwanese are willing to take part in the development of small or medium-sized firms, and they are qualified and capable,” Kosuda said.
The company had considered launching its IPO in China or South Korea, but chose Taiwan, as it has transparent regulations governing financial activities, he said.
In addition, given the good relations between Taiwan and Japan, the company expects smooth cooperation between experts, regulators and research agencies in the two nations, he said.
“Taiwan is the gateway for us to expand to other Asian markets,” Kosuda said.
The company plans to list on the Taipei Exchange or the Taiwan Stock Exchange, depending on its revenue or net value in 2021, CTBC Securities senior vice president Peng Fang-ying (彭芳英) told the Taipei Times.
Working on ways to harness a person’s immune system to achieve anti-tumor immune responses, REGiMMUNE developed RGI-2001 to ameliorate graft versus host disease following the receipt of transplanted tissue from a genetically different person, the company said.
While RGI-2001 has been well tolerated by six patients in phase 1 clinical studies, in the phase 2a trial some patients treated with RGI-2001 saw a marked increased in the number of regulatory T-cells, a critical cell subset which can modulate the human body’s immune response, it said.
The company has gained approval from the US Food and Drug Administration (FDA) to conduct a phase-2b trial next month and plans to enroll 50 patients, Kosuda said.
The trial is expected to be completed by 2022, he said.
Whether a phase-3 trial will be conducted depends on the results of the phase-2b trial and the FDA, he added.
PROTECTIONISM: China hopes to help domestic chipmakers gain more market share while preparing local tech companies for the possibility of more US sanctions Beijing is stepping up pressure on Chinese companies to buy locally produced artificial intelligence (AI) chips instead of Nvidia Corp products, part of the nation’s effort to expand its semiconductor industry and counter US sanctions. Chinese regulators have been discouraging companies from purchasing Nvidia’s H20 chips, which are used to develop and run AI models, sources familiar with the matter said. The policy has taken the form of guidance rather than an outright ban, as Beijing wants to avoid handicapping its own AI start-ups and escalating tensions with the US, said the sources, who asked not to be identified because the
FALLING BEHIND: Samsung shares have declined more than 20 percent this year, as the world’s largest chipmaker struggles in key markets and plays catch-up to rival SK Hynix Samsung Electronics Co is laying off workers in Southeast Asia, Australia and New Zealand as part of a plan to reduce its global headcount by thousands of jobs, sources familiar with the situation said. The layoffs could affect about 10 percent of its workforces in those markets, although the numbers for each subsidiary might vary, said one of the sources, who asked not to be named because the matter is private. Job cuts are planned for other overseas subsidiaries and could reach 10 percent in certain markets, the source said. The South Korean company has about 147,000 in staff overseas, more than half
Taipei is today suspending its US$2.5 trillion stock market as Super Typhoon Krathon approaches Taiwan with strong winds and heavy rain. The nation is not conducting securities, currency or fixed-income trading, statements from its stock and currency exchanges said. Yesterday, schools and offices were closed in several cities and counties in southern and eastern Taiwan, including in the key industrial port city of Kaohsiung. Taiwan, which started canceling flights, ship sailings and some train services earlier this week, has wind and rain advisories in place for much of the island. It regularly experiences typhoons, and in July shut offices and schools as
CHEMICAL FIRE: 10 Indian employees were injured by smoke inhalation at a Tata Electronics plant in Tamil Nadu state that produces components for Apple Inc At least 10 people received medical treatment, with two hospitalized after a major fire on Saturday disrupted production at a key Tata Electronics Pvt Ltd plant in southern India that makes Apple Inc’s iPhone components. The fire occurred at the plant in the city of Hosur in Tamil Nadu state that makes some iPhone components. It broke out near another building inside the Tata complex, which was to begin producing complete iPhones in the coming months. The fire was contained to one building and has been extinguished fully, top district administrative official K.M. Sarayu said. No decision has been made on when